WWL70

WWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells. WWL70 (either 1 or 10 μM) completely blocks the lipopolysaccharide (LPS)-induced increase of PGE2. The enhanced mRNA expression of mPGES-1 and mPGES-2 by LPS is also reduced by WWL70. The IC50 of WWL70 to inhibit the PGE2 biosynthesis is about 100 nM.WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %). WWL70 treatment improves motor coordination of traumatic brain injury mice in a concentration-dependent manner. The latency to fall in animals treated with WWL70 (5 mg/kg) increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. WWL70 (10 mg/kg) treatment improves motor coordination starting on day 1 post-injury.